Page last updated: 2024-11-11

aurachin c

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aurachin C: extracted from myxobacterium, Stigmatella aurantiaca strain Sg a15; MF: C25-H33-N-O2; MW: 379; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

aurachin C : A C-type aurachin that is quinolin-4-one which is substituted by a hydroxy group at positions 1, a methyl group at position 2, and a triprenyl group at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6439171
CHEMBL ID572434
CHEBI ID90888
SCHEMBL ID15094711
SCHEMBL ID16553028
MeSH IDM0148024

Synonyms (13)

Synonym
aurachin c
1-hydroxy-2-methyl-3-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]quinolin-4(1h)-one
CHEMBL572434
1-hydroxy-2-methyl-3-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trienyl]quinolin-4-one
108354-14-9
4(1h)-quinolinone, 1-hydroxy-2-methyl-3-(3,7,11-trimethyl-2,6,10-dodecatrienyl)-
aurachin-c
CHEBI:90888
SCHEMBL15094711
SCHEMBL16553028
C21330
Q27162864
DTXSID701318431
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
EC 1.8.5.4 (sulfide:quinone reductase) inhibitorAn EC 1.8.5.* (oxidoreductase acting on sulfur group donors, quinone or similar as acceptor) inhibitor that interferes with the action of sulfide:quinone reductase (EC 1.8.5.4).
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
C-type aurachinAny aurachin in which the farnesyl residue is positioned at C3 of the quinoline core (cf. A-type aurachin, in which the farnesyl residue is positioned at C4). C-type aurachins are converted into A-type aurachins by late stage tailoring reactions.
hydroxylaminesHydroxylamine, H2N-OH, and its hydrocarbyl derivatives.
quinolone
organic heterobicyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
sulfide oxidation I (sulfide-quinone reductase)53
aurachin A, B, C and D biosynthesis1026

Bioassays (4)

Assay IDTitleYearJournalArticle
AID436172Inhibition of respiration in bovine heart submitochondrial particles assessed as NADH oxidation2008Journal of natural products, Nov, Volume: 71, Issue:11
Semisynthesis and antiplasmodial activity of the quinoline alkaloid aurachin E.
AID436174Cytotoxicity against mouse L929 cells after 5 days by MTT assay2008Journal of natural products, Nov, Volume: 71, Issue:11
Semisynthesis and antiplasmodial activity of the quinoline alkaloid aurachin E.
AID436171Antiplasmodial activity against Plasmodium falciparum D6 clone after 48 hrs2008Journal of natural products, Nov, Volume: 71, Issue:11
Semisynthesis and antiplasmodial activity of the quinoline alkaloid aurachin E.
AID436170Antiplasmodial activity against Plasmodium falciparum W2 after 48 hrs2008Journal of natural products, Nov, Volume: 71, Issue:11
Semisynthesis and antiplasmodial activity of the quinoline alkaloid aurachin E.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (8.33)18.7374
1990's4 (33.33)18.2507
2000's3 (25.00)29.6817
2010's4 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.31 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]